<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005897</article-id><article-id pub-id-type="pmc">PMC11860268</article-id><article-id pub-id-type="doi">10.3390/vetsci12020137</article-id><article-id pub-id-type="publisher-id">vetsci-12-00137</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Early Enhancement in Contrast-Enhanced Computed Tomography Is an Index of <italic toggle="yes">DUSP9</italic>, <italic toggle="yes">SLPI</italic>, <italic toggle="yes">ALDH1L2</italic>, and <italic toggle="yes">SLC1A1</italic> Expression in Canine Hepatocellular Carcinoma: A Preliminary Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7911-913X</contrib-id><name><surname>Tanaka</surname><given-names>Toshiyuki</given-names></name><xref rid="af1-vetsci-12-00137" ref-type="aff">1</xref><xref rid="fn1-vetsci-12-00137" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6811-0973</contrib-id><name><surname>Motegi</surname><given-names>Tomoki</given-names></name><xref rid="af2-vetsci-12-00137" ref-type="aff">2</xref><xref rid="fn1-vetsci-12-00137" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Sumikawa</surname><given-names>Nanami</given-names></name><xref rid="af3-vetsci-12-00137" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Mori</surname><given-names>Misaki</given-names></name><xref rid="af3-vetsci-12-00137" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Kurokawa</surname><given-names>Shohei</given-names></name><xref rid="af1-vetsci-12-00137" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Akiyoshi</surname><given-names>Hideo</given-names></name><xref rid="af1-vetsci-12-00137" ref-type="aff">1</xref><xref rid="c1-vetsci-12-00137" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>van der Weyden</surname><given-names>Louise</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00137"><label>1</label>Laboratory of Veterinary Advanced Diagnosis and Treatment, School of Veterinary Science, Osaka Metropolitan University, Osaka 5988531, Japan; <email>f21724w@omu.ac.jp</email> (T.T.); <email>s.kurokawa@hs-gac.jp</email> (S.K.)</aff><aff id="af2-vetsci-12-00137"><label>2</label>Section of Computational Biomedicine, Department of Medicine, Boston University Chobanian &#x00026; Avedisian School of Medicine, Boston, MA 02118, USA; <email>a-t.motegi@g.ecc.u-tokyo.ac.jp</email></aff><aff id="af3-vetsci-12-00137"><label>3</label>Laboratory of Veterinary Surgery, School of Veterinary Science, Osaka Metropolitan University, Osaka 5988531, Japan; <email>sdc01019@st.osakafu-u.ac.jp</email> (N.S.); <email>sdc01041@st.osakafu-u.ac.jp</email> (M.M.)</aff><author-notes><corresp id="c1-vetsci-12-00137"><label>*</label>Correspondence: <email>h.akiyoshi@omu.ac.jp</email>; Tel.: +81-6-6977-3000</corresp><fn id="fn1-vetsci-12-00137"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>137</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>Genetic alterations affect the prognosis and treatment of human hepatocellular carcinoma (HCC). Research has begun to assess genetic alterations using minimally invasive and reproducible computed tomography (CT). However, the relationship between CT findings and the genomic information of canine HCC is unknown. In this study, we aimed to investigate the relationship between enhancement patterns in the arterial phase of CT imaging and gene expression in canine HCC using RNA sequencing. Based on the CT findings, three of the eight dogs studied were classified as having enhancement HCC and five as having non-enhancement HCC. RNA sequencing was performed using the mRNA extracted from the specimens. <italic toggle="yes">DUSP9</italic>, <italic toggle="yes">SLPI</italic>, and <italic toggle="yes">ALDH1L2</italic> were the most upregulated genes in enhancement HCC, whereas <italic toggle="yes">SLC1A1</italic> was the most downregulated gene in non-enhancement HCC. Canine HCC may involve different angiogenesis mechanisms. CT findings can be used to assess the gene expression status in canine HCC and may add new value to CT imaging.</p></abstract><abstract><title>Abstract</title><p>Canine hepatocellular carcinoma (HCC) is characterized by distinct computed tomography (CT) findings. HCC exhibits tumor heterogeneity, with different genomic information and histopathological features within the same tumor. In human HCC, genetic alterations affect the prognosis and treatment, and research has begun to assess genetic alterations using minimally invasive and reproducible CT. However, the relationship between CT findings and the genomic information of canine HCC is unknown. Early contrast of HCC indicates increased intratumoral neovascular growth. In this study, we aimed to investigate the relationship between enhancement patterns in the arterial phase of CT imaging and gene expression in canine HCC using RNA sequencing. Based on the CT findings, three of the eight dogs studied were classified as having enhancement HCC and five as having non-enhancement HCC. RNA sequencing was performed using the mRNA extracted from the specimens. Eight differentially expressed genes met the cutoff criteria. Among these, <italic toggle="yes">DUSP9</italic>, <italic toggle="yes">SLPI</italic>, and <italic toggle="yes">ALDH1L2</italic> were the most upregulated genes in enhancement HCC, whereas <italic toggle="yes">SLC1A1</italic> was the most downregulated in non-enhancement HCC. Canine HCC may involve different angiogenesis mechanisms. CT findings can be used to assess the gene expression status in canine HCC and may add new value to CT imaging.</p></abstract><kwd-group><kwd>dog</kwd><kwd>HCC</kwd><kwd>liver</kwd><kwd>radiogenomics</kwd><kwd>RNA sequence</kwd></kwd-group><funding-group><award-group><funding-source>JSPS KAKENHI</funding-source><award-id>22K05991</award-id></award-group><funding-statement>This study was supported by JSPS KAKENHI (grant number: 22K05991).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00137"><title>1. Introduction</title><p>Computed tomography (CT) is often used in veterinary medicine to differentiate liver tumors and evaluate their site of origin. Canine hepatocellular carcinoma (HCC) is characterized by distinct CT findings in individual cases, including early, heterogeneous, and reduced enhancement [<xref rid="B1-vetsci-12-00137" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-12-00137" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-12-00137" ref-type="bibr">3</xref>].</p><p>CT, positron emission tomography, and magnetic resonance imaging provide a three-dimensional global view of imaging features that reflect tumor heterogeneity [<xref rid="B4-vetsci-12-00137" ref-type="bibr">4</xref>,<xref rid="B5-vetsci-12-00137" ref-type="bibr">5</xref>]. HCC exhibits tumor heterogeneity with different types of genomic information and histopathological features within the same tumor (intratumoral heterogeneity) [<xref rid="B4-vetsci-12-00137" ref-type="bibr">4</xref>]. Genetic alterations in human HCC affect prognosis and treatment outcomes [<xref rid="B6-vetsci-12-00137" ref-type="bibr">6</xref>]. The diagnosis and treatment of HCC in humans are based on genomic and histopathological features [<xref rid="B4-vetsci-12-00137" ref-type="bibr">4</xref>]. However, caution should be exercised when assessing genomic information from biopsy tissues because the information obtained is valid only for a portion of the tumor and not for the entire HCC [<xref rid="B7-vetsci-12-00137" ref-type="bibr">7</xref>]. Imaging studies have been used to evaluate entire tumors in a minimally invasive and reproducible manner [<xref rid="B4-vetsci-12-00137" ref-type="bibr">4</xref>]. Although limited, CT and magnetic resonance imaging findings have been associated with gene expression profiles in human HCC [<xref rid="B8-vetsci-12-00137" ref-type="bibr">8</xref>,<xref rid="B9-vetsci-12-00137" ref-type="bibr">9</xref>]. Grouping various CT findings, such as the internal arteries, has revealed specific genomic information for each finding [<xref rid="B8-vetsci-12-00137" ref-type="bibr">8</xref>]. However, there have been limited reports on gene expression in canine HCC [<xref rid="B10-vetsci-12-00137" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00137" ref-type="bibr">11</xref>,<xref rid="B12-vetsci-12-00137" ref-type="bibr">12</xref>].</p><p>RNA sequencing (RNA-Seq) is an indispensable tool for transcriptome-wide analysis that enables the study of differential gene expression and mRNA splicing [<xref rid="B13-vetsci-12-00137" ref-type="bibr">13</xref>]. Although the CT findings of canine HCC include early contrast and no contrast-enhancing effects, the molecular differences and cancer characteristics associated with these typical findings remain to be elucidated. Early contrast in HCC indicates increased intratumoral neovascular growth [<xref rid="B14-vetsci-12-00137" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-12-00137" ref-type="bibr">15</xref>]. We hypothesized that the molecular differences between early contrast-enhancing and non-contrast-enhancing HCCs would reveal the mechanisms of angiogenesis and characterize HCC in dogs. In this study, we aimed to investigate the relationship between enhancement patterns in the arterial phase of CT imaging and gene expression in canine HCC using RNA-Seq.</p></sec><sec id="sec2-vetsci-12-00137"><title>2. Materials and Methods</title><p>For this study, dogs histopathologically diagnosed with HCC (n = 8) and those with normal livers (n = 4) were selected. Liver specimens were obtained during liver tumor resection at Osaka Metropolitan University Veterinary Medical Center, Japan. The inclusion criteria for this study were as follows: (1) histopathological diagnosis of HCC and (2) contrast-enhanced CT examination. The exclusion criterion was the presence of different CT findings for the same HCC. Specimens were collected in conjunction with CT imaging findings to match the exact locations of the enhancement and non-enhancement areas in the arterial phase. Livers of dogs with no histopathological abnormalities were used as normal liver specimens. Specimens for tissue banking were placed in a liquid nitrogen bath, snap-frozen, and stored at &#x02212;80 &#x000b0;C.</p><p>CT was performed using an Activion 16 (Canon Medical Systems Corporation, Tochigi, Japan) multidetector 16-slice CT scanner in helical scan mode, according to a previously reported protocol [<xref rid="B16-vetsci-12-00137" ref-type="bibr">16</xref>]. All dogs were placed under general anesthesia, ventilated, and in a supine position. Ventilation was paused during image authacquisition to induce apnea. For contrast-enhanced studies, 2 mL/kg iohexol, a non-ionic contrast medium (300 mgI/mL; Ioverin 300; Teva Pharma Japan, Inc., Aichi, Japan), was administered. The injection duration was 20 s. Contrast-enhanced studies were performed during the arterial (20 s after injection of the contrast medium), portal (60 s after injection of the contrast medium), and equilibrium (180 s after injection of the contrast medium) phases. The CT images were displayed in an abdominal window setting (window level = 35 Hounsfield Unit (HU), window width = 360 HU) to assess the liver neoplasms on a computer workstation using digital imaging and communications in medicine image-viewing software (Horos software ver. 2.4.1, Horos Project, Minneapolis, MN, USA). The CT images were reviewed by a veterinarian with over 10 years of experience as a radiologist. The mean attenuation of the HCC and the adjacent liver was measured on arterial-phase post-contrast images. The region of interest was manually drawn thrice to encompass the lesion. The mean HU values and standard deviations (SDs) of the lesions in the arterial-phase images were calculated. Necrotic and cystic areas confirmed both grossly and histopathologically were excluded when defining the CT findings. Statistical calculations were performed using R version 4.4.2 (R Core Team (2024). _R: A Language and Environment for Statistical Computing_. R Foundation for Statistical Computing, Vienna, Austria. &#x0003c;<uri xlink:href="https://www.R-project.org/">https://www.R-project.org/</uri>&#x0003e; accessed on 2 December 2024). Normalization of attenuation was assessed using the Shapiro&#x02013;Wilk test, which indicated that parametric testing was required. Results with <italic toggle="yes">p</italic>-values less than 0.05 were considered significant. According to the literature [<xref rid="B8-vetsci-12-00137" ref-type="bibr">8</xref>], the enhancement of HCC is defined as the presence of discrete arteries within the tumor and a statistically higher enhancement of the tumor compared with the adjacent liver. A non-enhancement tumor was defined as one that exhibited statistically lesser enhancement in the arterial phase than in the adjacent liver.</p><p>Total RNA was extracted from frozen liver tissues using the NucleoSpin<sup>&#x000ae;</sup> RNA Plus kit (Takara Bio Inc., Shiga, Japan) following the manufacturer&#x02019;s protocol. The purity and concentration of the isolated RNA were assessed by measuring the absorbance ratio at 260/280 nm (A260/A280) using an Eppendorf Biophotometer (Eppendorf, Hamburg, Germany).</p><p>The isolated samples were analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and samples with an RNA Integrity Number greater than 7.0 were selected for further experiments. RNA-Seq was performed using a NextSeq 500 system (Illumina K.K., Osaka, Japan). Quality control and adaptor trimming of the obtained fastq files for each sample were performed using FASTP. After trimming, the raw count data were obtained using a previously published pipeline [<xref rid="B17-vetsci-12-00137" ref-type="bibr">17</xref>]. Differentially expressed genes (DEGs) were identified using a generalized linear model in edgeR-based R packages (TCC v1.38.0), and significant groups were distinguished using the baySeq package (v2.32.0) in R. The <italic toggle="yes">q</italic> values were calculated from the <italic toggle="yes">p</italic>-values using the Benjamini&#x02013;Hochberg method, and the false discovery rate was set at <italic toggle="yes">q</italic> &#x0003c; 0.01.</p></sec><sec sec-type="results" id="sec3-vetsci-12-00137"><title>3. Results</title><p>Based on the CT findings of HCC, three of the eight dogs were classified as having enhancement HCC and five as having non-enhancement HCC. On enhancement HCC, the mean HU was 112.3 &#x000b1; 6.4 and 85.0 &#x000b1; 3.1 for lesion and adjacent liver, respectively. The mean HU of enhancement HCC in arterial-phase images was significantly higher than that of the adjacent liver (<italic toggle="yes">p</italic> &#x0003c; 0.05, <xref rid="vetsci-12-00137-f001" ref-type="fig">Figure 1</xref>). On non-enhancement HCC, the mean HU was 65.2 &#x000b1; 17.4 and 98.3 &#x000b1; 25.8 for lesion and adjacent liver, respectively. The mean HU of non-enhancement HCC in arterial-phase images was significantly lower than that of the adjacent liver tissue (<italic toggle="yes">p</italic> &#x0003c; 0.05, <xref rid="vetsci-12-00137-f002" ref-type="fig">Figure 2</xref>). Representative figures of the enhancement and non-enhancement HCC are shown in <xref rid="vetsci-12-00137-f001" ref-type="fig">Figure 1</xref> and <xref rid="vetsci-12-00137-f002" ref-type="fig">Figure 2</xref>.</p><p>The dogs with enhancement HCC included one neutered male, one intact male, and one intact female. The mean age of the dogs was 10.8 &#x000b1; 2.9 year (mean &#x000b1; SD). The dog breeds were as follows: one West Highland White Terrier, one Toy Poodle, and one Dachshund. Dogs with non-enhancement HCC included one intact male, one neutered female, and three intact females. The mean age of the dogs was 10.4 &#x000b1; 2.7 years (mean &#x000b1; SD). The dog breeds included three Shiba Inu, one Border Collie, and one Brussels Griffon. All dogs with HCC underwent surgical removal. The dogs were followed up without treatment for two years. None of the dogs with enhancement or non-enhancement HCC had postoperative recurrence or metastasis. The dogs with normal livers included four intact female Beagles with a mean age of 3.2 &#x000b1; 1.4 years (mean &#x000b1; SD). Dogs with normal livers, enhancement HCC, and non-enhancement HCC were grouped as G1, G2, and G3, respectively. The clinical findings are summarized in <xref rid="vetsci-12-00137-t001" ref-type="table">Table 1</xref>. Eight DEGs met the cutoff criteria (<xref rid="vetsci-12-00137-t002" ref-type="table">Table 2</xref>). Among these, <italic toggle="yes">DUSP9</italic>, <italic toggle="yes">SLPI</italic>, and <italic toggle="yes">ALDH1L2</italic> were the most upregulated in enhancement HCC, whereas <italic toggle="yes">TRPV6</italic> was the most upregulated in the normal liver. Furthermore, <italic toggle="yes">SLC1A1</italic> was the most downregulated in non-enhancement HCC, whereas <italic toggle="yes">TOP2A</italic> and <italic toggle="yes">CENPF</italic> were the most downregulated in the normal liver. One gene (Ensembl gene ID: ENSCAFG00000047783) was excluded from the analyses because its status was retired in the ROS_Cfam_1.0 assembly.</p></sec><sec sec-type="discussion" id="sec4-vetsci-12-00137"><title>4. Discussion</title><p>In this study, <italic toggle="yes">DUSP9</italic>, <italic toggle="yes">SLPI</italic>, and <italic toggle="yes">ALDH1L2</italic> were upregulated in canine-enhancement HCC. The enhancement of HCC in the arterial phase indicates increased intratumoral neovascular growth [<xref rid="B14-vetsci-12-00137" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-12-00137" ref-type="bibr">15</xref>]. In human HCC, <italic toggle="yes">VEGF</italic>, <italic toggle="yes">FGF</italic>, <italic toggle="yes">PDGF</italic>, and <italic toggle="yes">ANGPT</italic> promote angiogenesis [<xref rid="B18-vetsci-12-00137" ref-type="bibr">18</xref>]. However, in this study, enhancement HCC did not show overexpression of <italic toggle="yes">VEGF</italic>, <italic toggle="yes">FGF</italic>, <italic toggle="yes">PDGF</italic>, or <italic toggle="yes">ANGPT</italic> (<xref rid="app1-vetsci-12-00137" ref-type="app">Supplementary Material Table S1</xref>). Secretory leukocyte protease inhibitors (SLPIs) can affect tumor cell behavior and sinusoidal vasculature formation [<xref rid="B19-vetsci-12-00137" ref-type="bibr">19</xref>]. SLPI is a promising anti-inflammatory agent that is synthesized and released mainly by epithelial and inflammatory cells [<xref rid="B20-vetsci-12-00137" ref-type="bibr">20</xref>,<xref rid="B21-vetsci-12-00137" ref-type="bibr">21</xref>]. However, SLPI-induced angiogenesis is not driven by the usual angiogenic processes (endothelial cell proliferation, vascular extension, and tube formation) but rather occurs through a specific remodeling process in coordination with other molecules such as hypoxia-related angiogenic factors and necrosis-induced cytokines [<xref rid="B19-vetsci-12-00137" ref-type="bibr">19</xref>]. Considering the expression levels of <italic toggle="yes">VEGF</italic>, <italic toggle="yes">FGF</italic>, <italic toggle="yes">PDGF</italic>, and <italic toggle="yes">ANGPT</italic>, <italic toggle="yes">SLPI</italic> may be primarily involved in angiogenesis in canine-enhancement HCC, unlike in humans. Unlike human HCC, <italic toggle="yes">SLPI</italic> in canine HCC may be involved in angiogenesis. This study only assessed the mRNA expression levels in canine HCC. Further investigation using histopathological techniques is required to clarify the relationship between <italic toggle="yes">SLPI</italic> and angiogenesis.</p><p>A strong correlation exists between aberrant SLPI expression and the development of various human cancers, including lung, ovarian, cervical, neck, and pancreatic tumors [<xref rid="B21-vetsci-12-00137" ref-type="bibr">21</xref>]. In human HCC, SLPI suppressed the proliferation, migration, and invasion capabilities of HCC cells in vitro, whereas ectopic SLPI expression inhibited their tumorigenicity in vivo [<xref rid="B22-vetsci-12-00137" ref-type="bibr">22</xref>]. SLPI regulates the proliferation, migration, and invasion capabilities of HCC cells via apoptosis through the mitogen-activated protein kinase (MAPK) signaling pathway [<xref rid="B22-vetsci-12-00137" ref-type="bibr">22</xref>], indicating its potential as both a tumor suppressor and a biomarker for HCC prognosis and treatment [<xref rid="B21-vetsci-12-00137" ref-type="bibr">21</xref>]. In this study, neither enhancement nor non-enhancement HCC showed postoperative recurrence or metastasis. Further studies in canine HCC cases are required to determine the relationship between <italic toggle="yes">SLPI</italic> expression and HCC prognosis.</p><p>Dual-specificity phosphatase (DUSP), also referred to as MAPK phosphatase, modulates MAPK activity by dephosphorylating phosphotyrosine and phosphoserine/phosphothreonine residues on extracellular signal-regulated kinase, c-Jun N-terminal kinase, and p38 [<xref rid="B23-vetsci-12-00137" ref-type="bibr">23</xref>]. DUSP has been increasingly recognized for participating in various cellular processes [<xref rid="B24-vetsci-12-00137" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00137" ref-type="bibr">25</xref>]. The expression of DUSP9 is elevated in human HCC [<xref rid="B26-vetsci-12-00137" ref-type="bibr">26</xref>,<xref rid="B27-vetsci-12-00137" ref-type="bibr">27</xref>]. Elevated DUSP9 expression is linked to reduced disease-free survival and an increased risk of recurrence following liver resection [<xref rid="B27-vetsci-12-00137" ref-type="bibr">27</xref>]. In humans, reports on the expression of DUSP9 in HCC are conflicting, with a few studies reporting decreased expression [<xref rid="B28-vetsci-12-00137" ref-type="bibr">28</xref>]. Overexpression of DUSP9 correlates with a good prognosis [<xref rid="B28-vetsci-12-00137" ref-type="bibr">28</xref>].</p><p>In humans, <italic toggle="yes">ALDH1L2</italic> mRNA expression is associated with the histopathological grade of HCC [<xref rid="B29-vetsci-12-00137" ref-type="bibr">29</xref>]. Grades 1&#x02013;3 of HCC indicate significantly higher aldehyde dehydrogenase 1 family member L2 (ALDH1L2) expression than that in the normal liver, while grade 4 indicates no difference [<xref rid="B29-vetsci-12-00137" ref-type="bibr">29</xref>]. To the best of our knowledge, no grading scale is currently available for canine HCC [<xref rid="B30-vetsci-12-00137" ref-type="bibr">30</xref>]. In breast cancer, ALDH1L2 suppresses reactive oxygen species production and is involved in the MAPK pathway [<xref rid="B31-vetsci-12-00137" ref-type="bibr">31</xref>]. The mechanism of action of ALDH1L2 in human HCC remains unclear; however, in canine HCC, <italic toggle="yes">SLPI</italic>, <italic toggle="yes">DUSP9</italic>, and <italic toggle="yes">ALDH1L2</italic> may be involved in the MAPK pathway. Furthermore, the expression of <italic toggle="yes">SLPI</italic>, <italic toggle="yes">DUSP9</italic>, and <italic toggle="yes">ALDH1L2</italic> in canine HCC and their effects remain unclear. Considering the effects of <italic toggle="yes">SLPI</italic>, <italic toggle="yes">DUSP9</italic>, and <italic toggle="yes">ALDH1L2</italic> in humans, overexpression of these genes in canine-enhancement HCC may indicate lower malignancy. However, a massive canine HCC indicates low systemic progression and a favorable long-term prognosis [<xref rid="B32-vetsci-12-00137" ref-type="bibr">32</xref>]. Further studies are required to investigate the relationship between the overexpression of <italic toggle="yes">SLPI</italic>, <italic toggle="yes">DUSP9</italic>, and <italic toggle="yes">ALDH1L2</italic> and their influence on the enhancement of HCC.</p><p>Solute carrier family 1 (SLC1)A1 functions as a glutamate transporter in neurons, retinal ganglion cells, and glial cells [<xref rid="B33-vetsci-12-00137" ref-type="bibr">33</xref>,<xref rid="B34-vetsci-12-00137" ref-type="bibr">34</xref>,<xref rid="B35-vetsci-12-00137" ref-type="bibr">35</xref>,<xref rid="B36-vetsci-12-00137" ref-type="bibr">36</xref>]. SLC1A1 is expressed outside the central nervous system, particularly in the intestine, liver, heart, skeletal muscle, kidneys, placenta, sciatic nerve, dorsal root ganglion, and primary afferent fibers terminating in the dorsal spinal horn [<xref rid="B33-vetsci-12-00137" ref-type="bibr">33</xref>]. Outside the brain, SLC1A1 appears to be the main glutamate and aspartate transporter in several cell types [<xref rid="B33-vetsci-12-00137" ref-type="bibr">33</xref>]. However, few studies have investigated the relationship between <italic toggle="yes">SLC1A1</italic> expression and cancer development. In human liver cancer, <italic toggle="yes">SLC1A1</italic> is downregulated compared with that in the normal liver [<xref rid="B37-vetsci-12-00137" ref-type="bibr">37</xref>]. In this study, <italic toggle="yes">SLC1A1</italic> was downregulated in non-enhancement HCC compared with that in normal liver. However, the implications of this downregulation in HCC remain unclear. In human lung adenocarcinoma, low <italic toggle="yes">SLC1A1</italic> expression is correlated with tumor stage, histological subtype, nodal metastasis status, and poor overall survival [<xref rid="B37-vetsci-12-00137" ref-type="bibr">37</xref>]. Further studies are required to assess the effects of <italic toggle="yes">SLC1A1</italic> downregulation on canine HCC.</p><p>CT is a noninvasive method for visualizing the internal tissues of the body, and the resulting images are crucial for clinical decision-making, including diagnosis and treatment [<xref rid="B38-vetsci-12-00137" ref-type="bibr">38</xref>]. The findings of this study suggest that CT findings can represent differences in mRNA expression levels and may help assess genomic information in the future. CT findings may have the potential to predict the prognosis and treatment response. This study has the potential to increase the amount of information obtained from CT findings and facilitate the adoption of noninvasive genetic evaluation in clinical practice.</p><p>This study had certain limitations. First, this study included a biased and small number of dogs with enhancement HCC. Benign masses, such as nodular hyperplasia and hepatocellular adenomas, show significant enhancement compared with the adjacent liver during the arterial phase [<xref rid="B1-vetsci-12-00137" ref-type="bibr">1</xref>,<xref rid="B2-vetsci-12-00137" ref-type="bibr">2</xref>,<xref rid="B3-vetsci-12-00137" ref-type="bibr">3</xref>]. No preoperative biopsy was performed at our institution. Therefore, few cases were followed up without surgery and were not included in this study. This may have resulted in a low number of cases of enhancement HCC. This study evaluated the enhancement in the arterial phase using CT findings and genomic information. However, HCC presents various CT characteristics, such as contrast effects in the portal and equilibrium phases, necrosis, and tumor size. Combining multiple CT findings may allow for a more accurate assessment of genomic information. Moreover, we did not investigate the effect of <italic toggle="yes">DUSP9</italic>, <italic toggle="yes">SLPI</italic>, or <italic toggle="yes">ALDH1L2</italic> on angiogenesis. Only DEGs observed in canine-enhancement HCC were identified, and how <italic toggle="yes">DUSP9</italic>, <italic toggle="yes">SLPI</italic>, and <italic toggle="yes">ALDH1L2</italic> influence the imaging findings remains unclear. Therefore, further studies on canine HCC cases are required to investigate the relationship between CT findings and genomic information. Second, the age differences between the normal liver and hepatocellular carcinoma may have influenced the DEGs in HCC. The main objective of this study was to determine differences in genomic information between enhancement and non-enhancement HCC. Therefore, we hypothesized that age-related genomic changes do not significantly affect healthy dogs. Third, protein expression levels could not be evaluated in this study; although RNA samples were collected, tissue samples were not preserved for protein expression analyses. Therefore, the function and activity of DUSP9, ALDH1L2, and SLPI could not be evaluated.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00137"><title>5. Conclusions</title><p>CT findings in canine HCC may indicate differences in mRNA expression levels. These findings can predict the gene expression status in canine HCC, thereby adding new value to CT imaging.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the staff of the Veterinary Medical Center of Osaka Metropolitan University for their help in caring for the dogs.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00137"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci12020137/s1">https://www.mdpi.com/article/10.3390/vetsci12020137/s1</uri>. Table S1. All DEGs among enhancement HCC, non-enhancement HCC, and normal liver.</p><supplementary-material id="vetsci-12-00137-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00137-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>T.T. served as the principal investigator. T.T. and T.M. are the first authors of this manuscript. T.T. and H.A. conceived the study while H.A. supervised the surveillance components. M.M. and N.S. performed specimen sampling and RNA isolation. T.M. validated and analyzed the RNA-Seq data. T.M., T.T., M.M., N.S., and S.K. interpreted the RNA-Seq data. T.T. prepared the initial drafts, figures, and tables. All authors contributed to the writing and editing of the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Informed consent was obtained from all clients during the first examination of their dogs for the collection of HCC samples in this study. The normal liver tissue was a piece of liver collected and cryopreserved as part of a separate project that was conducted in accordance with the Guidelines of Animal Care and Use at Osaka Metropolitan University (Accession numbers 20-114 and 20-115).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all clients during the first examination of their dogs for the publication of HCC case data in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data have been deposited with links to BioProject, accession number PRJDB 18013, in the DDBJ BioProject database (<uri xlink:href="https://identifiers.org/bioproject:PRJDB18013">https://identifiers.org/bioproject:PRJDB18013</uri>) accessd on 2 December 2024. HCC cases with CT images included in PRJDB 18013 were used for the analysis. Normal liver samples included SAMD00771057, SAMD00771058, SAMD00771059, and SAMD00771060. Enhancement HCC samples included SAMD00771063, SAMD00771066, and SAMD00771067. Non-enhancement HCC samples included SAMD00771061, SAMD00771062, SAMD00771064, SAMD00771065, and SAMD00771068.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no potential conflicts of interest with respect to the research, authorship, or publication of this article.</p></notes><glossary><title>Abbreviations</title><array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">CT</td><td align="left" valign="middle" rowspan="1" colspan="1">Computed tomography</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DEG</td><td align="left" valign="middle" rowspan="1" colspan="1">Differentially expressed gene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DUSPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Dual-specificity phosphatases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Hepatocellular carcinoma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAPK</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitogen-activated protein kinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRI</td><td align="left" valign="middle" rowspan="1" colspan="1">Magnetic resonance imaging</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RNA-Seq</td><td align="left" valign="middle" rowspan="1" colspan="1">RNA sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SLC1</td><td align="left" valign="middle" rowspan="1" colspan="1">Solute carrier family 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SLPIs</td><td align="left" valign="middle" rowspan="1" colspan="1">Secretory leukocyte protease inhibitors</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-vetsci-12-00137"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kurokawa</surname><given-names>S.</given-names></name>
<name><surname>Tanaka</surname><given-names>T.</given-names></name>
<name><surname>Yamazaki</surname><given-names>H.</given-names></name>
<name><surname>Noguchi</surname><given-names>S.</given-names></name>
<name><surname>Wada</surname><given-names>Y.</given-names></name>
<name><surname>Nishida</surname><given-names>H.</given-names></name>
<name><surname>Akiyoshi</surname><given-names>H.</given-names></name>
</person-group><article-title>Comparing the CT and MRI findings for canine primary hepatocellular lesions</article-title><source>VetRecord</source><year>2022</year><volume>190</volume><fpage>e1083</fpage><pub-id pub-id-type="doi">10.1002/vetr.1083</pub-id><pub-id pub-id-type="pmid">34751436</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00137"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kutara</surname><given-names>K.</given-names></name>
<name><surname>Seki</surname><given-names>M.</given-names></name>
<name><surname>Ishikawa</surname><given-names>C.</given-names></name>
<name><surname>Sakai</surname><given-names>M.</given-names></name>
<name><surname>Kagawa</surname><given-names>Y.</given-names></name>
<name><surname>Iida</surname><given-names>G.</given-names></name>
<name><surname>Ishigaki</surname><given-names>K.</given-names></name>
<name><surname>Teshima</surname><given-names>K.</given-names></name>
<name><surname>Edamura</surname><given-names>K.</given-names></name>
<name><surname>Nakayama</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Triple-phase helical computed tomography in dogs with hepatic masses</article-title><source>Vet. Radiol. Ultrasound</source><year>2014</year><volume>55</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/vru.12099</pub-id><pub-id pub-id-type="pmid">24102918</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00137"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukushima</surname><given-names>K.</given-names></name>
<name><surname>Kanemoto</surname><given-names>H.</given-names></name>
<name><surname>Ohno</surname><given-names>K.</given-names></name>
<name><surname>Takahashi</surname><given-names>M.</given-names></name>
<name><surname>Nakashima</surname><given-names>K.</given-names></name>
<name><surname>Fujino</surname><given-names>Y.</given-names></name>
<name><surname>Uchida</surname><given-names>K.</given-names></name>
<name><surname>Fujiwara</surname><given-names>R.</given-names></name>
<name><surname>Nishimura</surname><given-names>R.</given-names></name>
<name><surname>Tsujimoto</surname><given-names>H.</given-names></name>
</person-group><article-title>CT characteristics of primary hepatic mass lesions in dogs</article-title><source>Vet. Radiol. Ultrasound</source><year>2012</year><volume>53</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1111/j.1740-8261.2011.01917.x</pub-id><pub-id pub-id-type="pmid">22244075</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00137"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wakabayashi</surname><given-names>T.</given-names></name>
<name><surname>Ouhmich</surname><given-names>F.</given-names></name>
<name><surname>Gonzalez-Cabrera</surname><given-names>C.</given-names></name>
<name><surname>Felli</surname><given-names>E.</given-names></name>
<name><surname>Saviano</surname><given-names>A.</given-names></name>
<name><surname>Agnus</surname><given-names>V.</given-names></name>
<name><surname>Savadjiev</surname><given-names>P.</given-names></name>
<name><surname>Baumert</surname><given-names>T.F.</given-names></name>
<name><surname>Pessaux</surname><given-names>P.</given-names></name>
<name><surname>Marescaux</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Radiomics in hepatocellular carcinoma: A quantitative review</article-title><source>Hepatol. Int.</source><year>2019</year><volume>13</volume><fpage>546</fpage><lpage>559</lpage><pub-id pub-id-type="doi">10.1007/s12072-019-09973-0</pub-id><pub-id pub-id-type="pmid">31473947</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00137"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gevaert</surname><given-names>O.</given-names></name>
<name><surname>Echegaray</surname><given-names>S.</given-names></name>
<name><surname>Khuong</surname><given-names>A.</given-names></name>
<name><surname>Hoang</surname><given-names>C.D.</given-names></name>
<name><surname>Shrager</surname><given-names>J.B.</given-names></name>
<name><surname>Jensen</surname><given-names>K.C.</given-names></name>
<name><surname>Berry</surname><given-names>G.J.</given-names></name>
<name><surname>Guo</surname><given-names>H.H.</given-names></name>
<name><surname>Lau</surname><given-names>C.</given-names></name>
<name><surname>Plevritis</surname><given-names>S.K.</given-names></name>
<etal/>
</person-group><article-title>Predictive radiogenomics modeling of EGFR mutation status in lung cancer</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>41674</elocation-id><pub-id pub-id-type="doi">10.1038/srep41674</pub-id><pub-id pub-id-type="pmid">28139704</pub-id>
</element-citation></ref><ref id="B6-vetsci-12-00137"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zucman-Rossi</surname><given-names>J.</given-names></name>
<name><surname>Villanueva</surname><given-names>A.</given-names></name>
<name><surname>Nault</surname><given-names>J.C.</given-names></name>
<name><surname>Llovet</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Genetic landscape and biomarkers of hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2015</year><volume>149</volume><fpage>1226</fpage><lpage>1239.e4</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.05.061</pub-id><pub-id pub-id-type="pmid">26099527</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00137"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>H.X.</given-names></name>
<name><surname>Lee</surname><given-names>A.M.</given-names></name>
<name><surname>Yang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>P.</given-names></name>
<name><surname>Davatzikos</surname><given-names>C.</given-names></name>
<name><surname>Maris</surname><given-names>J.M.</given-names></name>
<name><surname>Diskin</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Imaging genomics in cancer research: Limitations and promises</article-title><source>Br. J. Radiol.</source><year>2016</year><volume>89</volume><fpage>20151030</fpage><pub-id pub-id-type="doi">10.1259/bjr.20151030</pub-id><pub-id pub-id-type="pmid">26864054</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00137"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Segal</surname><given-names>E.</given-names></name>
<name><surname>Sirlin</surname><given-names>C.B.</given-names></name>
<name><surname>Ooi</surname><given-names>C.</given-names></name>
<name><surname>Adler</surname><given-names>A.S.</given-names></name>
<name><surname>Gollub</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Chan</surname><given-names>B.K.</given-names></name>
<name><surname>Matcuk</surname><given-names>G.R.</given-names></name>
<name><surname>Barry</surname><given-names>C.T.</given-names></name>
<name><surname>Chang</surname><given-names>H.Y.</given-names></name>
<etal/>
</person-group><article-title>Decoding global gene expression programs in liver cancer by noninvasive imaging</article-title><source>Nat. Biotechnol.</source><year>2007</year><volume>25</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/nbt1306</pub-id><pub-id pub-id-type="pmid">17515910</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00137"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hectors</surname><given-names>S.J.</given-names></name>
<name><surname>Wagner</surname><given-names>M.</given-names></name>
<name><surname>Bane</surname><given-names>O.</given-names></name>
<name><surname>Besa</surname><given-names>C.</given-names></name>
<name><surname>Lewis</surname><given-names>S.</given-names></name>
<name><surname>Remark</surname><given-names>R.</given-names></name>
<name><surname>Chen</surname><given-names>N.</given-names></name>
<name><surname>Fiel</surname><given-names>M.I.</given-names></name>
<name><surname>Zhu</surname><given-names>H.</given-names></name>
<name><surname>Gnjatic</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>2452</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-02706-z</pub-id><pub-id pub-id-type="pmid">28550313</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00137"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai</surname><given-names>Y.C.</given-names></name>
<name><surname>Ushio</surname><given-names>N.</given-names></name>
<name><surname>Rahman</surname><given-names>M.M.</given-names></name>
<name><surname>Katanoda</surname><given-names>Y.</given-names></name>
<name><surname>Ogihara</surname><given-names>K.</given-names></name>
<name><surname>Naya</surname><given-names>Y.</given-names></name>
<name><surname>Moriyama</surname><given-names>A.</given-names></name>
<name><surname>Iwanaga</surname><given-names>T.</given-names></name>
<name><surname>Saitoh</surname><given-names>Y.</given-names></name>
<name><surname>Sogawa</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Aberrant expression of microRNAs and the miR-1/MET pathway in canine hepatocellular carcinoma</article-title><source>Vet. Comp. Oncol.</source><year>2018</year><volume>16</volume><fpage>288</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1111/vco.12379</pub-id><pub-id pub-id-type="pmid">29314614</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00137"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Polak</surname><given-names>K.Z.</given-names></name>
<name><surname>Schaffer</surname><given-names>P.</given-names></name>
<name><surname>Donaghy</surname><given-names>D.</given-names></name>
<name><surname>Zenk</surname><given-names>M.C.</given-names></name>
<name><surname>Olver</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Iron, hepcidin, and microcytosis in canine hepatocellular carcinoma</article-title><source>Vet. Clin. Pathol.</source><year>2022</year><volume>51</volume><fpage>208</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1111/vcp.13085</pub-id><pub-id pub-id-type="pmid">35274348</pub-id>
</element-citation></ref><ref id="B12-vetsci-12-00137"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iida</surname><given-names>G.</given-names></name>
<name><surname>Asano</surname><given-names>K.</given-names></name>
<name><surname>Seki</surname><given-names>M.</given-names></name>
<name><surname>Sakai</surname><given-names>M.</given-names></name>
<name><surname>Kutara</surname><given-names>K.</given-names></name>
<name><surname>Ishigaki</surname><given-names>K.</given-names></name>
<name><surname>Kagawa</surname><given-names>Y.</given-names></name>
<name><surname>Yoshida</surname><given-names>O.</given-names></name>
<name><surname>Teshima</surname><given-names>K.</given-names></name>
<name><surname>Edamura</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Gene expression of growth factors and growth factor receptors for potential targeted therapy of canine hepatocellular carcinoma</article-title><source>J. Vet. Med. Sci.</source><year>2014</year><volume>76</volume><fpage>301</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1292/jvms.13-0378</pub-id><pub-id pub-id-type="pmid">24189579</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00137"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stark</surname><given-names>R.</given-names></name>
<name><surname>Grzelak</surname><given-names>M.</given-names></name>
<name><surname>Hadfield</surname><given-names>J.</given-names></name>
</person-group><article-title>RNA sequencing: The teenage years</article-title><source>Nat. Rev. Genet.</source><year>2019</year><volume>20</volume><fpage>631</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1038/s41576-019-0150-2</pub-id><pub-id pub-id-type="pmid">31341269</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00137"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tajima</surname><given-names>T.</given-names></name>
<name><surname>Honda</surname><given-names>H.</given-names></name>
<name><surname>Taguchi</surname><given-names>K.</given-names></name>
<name><surname>Asayama</surname><given-names>Y.</given-names></name>
<name><surname>Kuroiwa</surname><given-names>T.</given-names></name>
<name><surname>Yoshimitsu</surname><given-names>K.</given-names></name>
<name><surname>Irie</surname><given-names>H.</given-names></name>
<name><surname>Aibe</surname><given-names>H.</given-names></name>
<name><surname>Shimada</surname><given-names>M.</given-names></name>
<name><surname>Masuda</surname><given-names>K.</given-names></name>
</person-group><article-title>Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation</article-title><source>AJR Am. J. Roentgenol.</source><year>2002</year><volume>178</volume><fpage>885</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.2214/ajr.178.4.1780885</pub-id><pub-id pub-id-type="pmid">11906868</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00137"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsui</surname><given-names>O.</given-names></name>
<name><surname>Kobayashi</surname><given-names>S.</given-names></name>
<name><surname>Sanada</surname><given-names>J.</given-names></name>
<name><surname>Kouda</surname><given-names>W.</given-names></name>
<name><surname>Ryu</surname><given-names>Y.</given-names></name>
<name><surname>Kozaka</surname><given-names>K.</given-names></name>
<name><surname>Kitao</surname><given-names>A.</given-names></name>
<name><surname>Nakamura</surname><given-names>K.</given-names></name>
<name><surname>Gabata</surname><given-names>T.</given-names></name>
</person-group><article-title>Hepatocelluar nodules in liver cirrhosis: Hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis</article-title><source>Abdom. Imaging</source><year>2011</year><volume>36</volume><fpage>264</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1007/s00261-011-9685-1</pub-id><pub-id pub-id-type="pmid">21267562</pub-id>
</element-citation></ref><ref id="B16-vetsci-12-00137"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tanaka</surname><given-names>T.</given-names></name>
<name><surname>Iimori</surname><given-names>Y.</given-names></name>
<name><surname>Yamazaki</surname><given-names>H.</given-names></name>
<name><surname>Nishida</surname><given-names>H.</given-names></name>
<name><surname>Akiyoshi</surname><given-names>H.</given-names></name>
</person-group><article-title>Contrast-enhanced computed tomography characterization of canine rectal neoplasms</article-title><source>Jpn. J. Vet. Res.</source><year>2021</year><volume>69</volume><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.14943/jjvr.69.3.163</pub-id></element-citation></ref><ref id="B17-vetsci-12-00137"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maeda</surname><given-names>S.</given-names></name>
<name><surname>Motegi</surname><given-names>T.</given-names></name>
<name><surname>Iio</surname><given-names>A.</given-names></name>
<name><surname>Kaji</surname><given-names>K.</given-names></name>
<name><surname>Goto-Koshino</surname><given-names>Y.</given-names></name>
<name><surname>Eto</surname><given-names>S.</given-names></name>
<name><surname>Ikeda</surname><given-names>N.</given-names></name>
<name><surname>Nakagawa</surname><given-names>T.</given-names></name>
<name><surname>Nishimura</surname><given-names>R.</given-names></name>
<name><surname>Yonezawa</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e003731</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-003731</pub-id><pub-id pub-id-type="pmid">35131860</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00137"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zender</surname><given-names>L.</given-names></name>
<name><surname>Villanueva</surname><given-names>A.</given-names></name>
<name><surname>Tovar</surname><given-names>V.</given-names></name>
<name><surname>Sia</surname><given-names>D.</given-names></name>
<name><surname>Chiang</surname><given-names>D.Y.</given-names></name>
<name><surname>Llovet</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Cancer gene discovery in hepatocellular carcinoma</article-title><source>J. Hepatol.</source><year>2010</year><volume>52</volume><fpage>921</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2009.12.034</pub-id><pub-id pub-id-type="pmid">20385424</pub-id>
</element-citation></ref><ref id="B19-vetsci-12-00137"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sugino</surname><given-names>T.</given-names></name>
<name><surname>Yamaguchi</surname><given-names>T.</given-names></name>
<name><surname>Ogura</surname><given-names>G.</given-names></name>
<name><surname>Kusakabe</surname><given-names>T.</given-names></name>
<name><surname>Goodison</surname><given-names>S.</given-names></name>
<name><surname>Homma</surname><given-names>Y.</given-names></name>
<name><surname>Suzuki</surname><given-names>T.</given-names></name>
</person-group><article-title>The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway</article-title><source>J. Pathol.</source><year>2007</year><volume>212</volume><fpage>152</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1002/path.2156</pub-id><pub-id pub-id-type="pmid">17455170</pub-id>
</element-citation></ref><ref id="B20-vetsci-12-00137"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>Q.Q.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Y.F.</given-names></name>
<name><surname>Peng</surname><given-names>L.J.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.S.</given-names></name>
</person-group><article-title>Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis</article-title><source>Exp. Biol. Med.</source><year>2017</year><volume>242</volume><fpage>250</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1177/1535370216672747</pub-id><pub-id pub-id-type="pmid">27698252</pub-id>
</element-citation></ref><ref id="B21-vetsci-12-00137"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>S.S.</given-names></name>
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Qu</surname><given-names>W.</given-names></name>
</person-group><article-title>Secretory leukocyte protease inhibitor (SLPI) in cancer pathophysiology: Mechanisms of action and clinical implications</article-title><source>Pathol. Res. Pract.</source><year>2023</year><volume>248</volume><fpage>154633</fpage><pub-id pub-id-type="doi">10.1016/j.prp.2023.154633</pub-id><pub-id pub-id-type="pmid">37356220</pub-id>
</element-citation></ref><ref id="B22-vetsci-12-00137"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Z.</given-names></name>
<name><surname>Liang</surname><given-names>Y.</given-names></name>
<name><surname>Duan</surname><given-names>R.</given-names></name>
<name><surname>Zheng</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Kong</surname><given-names>D.</given-names></name>
</person-group><article-title>SLPI suppresses hepatocellular carcinoma progression via endoplasmic reticulum stress induced apoptosis</article-title><source>Int. J. Biol. Sci.</source><year>2022</year><volume>18</volume><fpage>140</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.7150/ijbs.65676</pub-id><pub-id pub-id-type="pmid">34975323</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00137"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patterson</surname><given-names>K.I.</given-names></name>
<name><surname>Brummer</surname><given-names>T.</given-names></name>
<name><surname>O&#x02019;Brien</surname><given-names>P.M.</given-names></name>
<name><surname>Daly</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Dual-specificity phosphatases: Critical regulators with diverse cellular targets</article-title><source>Biochem. J.</source><year>2009</year><volume>418</volume><fpage>475</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1042/BJ20082234</pub-id><pub-id pub-id-type="pmid">19228121</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00137"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kidger</surname><given-names>A.M.</given-names></name>
<name><surname>Keyse</surname><given-names>S.M.</given-names></name>
</person-group><article-title>The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)</article-title><source>Semin. Cell Dev. Biol.</source><year>2016</year><volume>50</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2016.01.009</pub-id><pub-id pub-id-type="pmid">26791049</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00137"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Seternes</surname><given-names>O.M.</given-names></name>
<name><surname>Kidger</surname><given-names>A.M.</given-names></name>
<name><surname>Keyse</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Dual-specificity MAP kinase phosphatases in health and disease</article-title><source>Biochim Biophys Acta Mol. Cell Res.</source><year>2019</year><volume>1866</volume><fpage>124</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2018.09.002</pub-id><pub-id pub-id-type="pmid">30401534</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00137"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Petrochilos</surname><given-names>D.</given-names></name>
<name><surname>Shojaie</surname><given-names>A.</given-names></name>
<name><surname>Gennari</surname><given-names>J.</given-names></name>
<name><surname>Abernethy</surname><given-names>N.</given-names></name>
</person-group><article-title>Using random walks to identify cancer-associated modules in expression data</article-title><source>BioData Min.</source><year>2013</year><volume>6</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1186/1756-0381-6-17</pub-id><pub-id pub-id-type="pmid">24128261</pub-id>
</element-citation></ref><ref id="B27-vetsci-12-00137"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>K.</given-names></name>
<name><surname>Gorgen</surname><given-names>A.</given-names></name>
<name><surname>Ding</surname><given-names>A.</given-names></name>
<name><surname>Du</surname><given-names>L.</given-names></name>
<name><surname>Jiang</surname><given-names>K.</given-names></name>
<name><surname>Ding</surname><given-names>Y.</given-names></name>
<name><surname>Sapisochin</surname><given-names>G.</given-names></name>
<name><surname>Ghanekar</surname><given-names>A.</given-names></name>
</person-group><article-title>Dual-specificity phosphatase 9 regulates cellular proliferation and predicts recurrence after surgery in hepatocellular carcinoma</article-title><source>Hepatol. Commun.</source><year>2021</year><volume>5</volume><fpage>1310</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1002/hep4.1701</pub-id><pub-id pub-id-type="pmid">34278178</pub-id>
</element-citation></ref><ref id="B28-vetsci-12-00137"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Ni</surname><given-names>W.</given-names></name>
<name><surname>Xiao</surname><given-names>M.</given-names></name>
<name><surname>Jiang</surname><given-names>F.</given-names></name>
<name><surname>Ni</surname><given-names>R.</given-names></name>
</person-group><article-title>Decreased expression and prognostic role of mitogen-activated protein kinase phosphatase 4 in hepatocellular carcinoma</article-title><source>J. Gastrointest. Surg.</source><year>2013</year><volume>17</volume><fpage>756</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1007/s11605-013-2138-0</pub-id><pub-id pub-id-type="pmid">23325341</pub-id>
</element-citation></ref><ref id="B29-vetsci-12-00137"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yao</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>W.</given-names></name>
<name><surname>Zuo</surname><given-names>H.</given-names></name>
<name><surname>Bi</surname><given-names>Z.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Pang</surname><given-names>L.</given-names></name>
<name><surname>Jing</surname><given-names>Y.</given-names></name>
<name><surname>Yin</surname><given-names>X.</given-names></name>
<name><surname>Cheng</surname><given-names>H.</given-names></name>
</person-group><article-title>Comprehensive analysis of aldehyde dehydrogenases (ALDHs) and its significant role in hepatocellular carcinoma</article-title><source>Biochem. Genet.</source><year>2022</year><volume>60</volume><fpage>1274</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1007/s10528-021-10178-0</pub-id><pub-id pub-id-type="pmid">34928471</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00137"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Avallone</surname><given-names>G.</given-names></name>
<name><surname>Rasotto</surname><given-names>R.</given-names></name>
<name><surname>Chambers</surname><given-names>J.K.</given-names></name>
<name><surname>Miller</surname><given-names>A.D.</given-names></name>
<name><surname>Behling-Kelly</surname><given-names>E.</given-names></name>
<name><surname>Monti</surname><given-names>P.</given-names></name>
<name><surname>Berlato</surname><given-names>D.</given-names></name>
<name><surname>Valenti</surname><given-names>P.</given-names></name>
<name><surname>Roccabianca</surname><given-names>P.</given-names></name>
</person-group><article-title>Review of histological grading systems in veterinary medicine</article-title><source>Vet. Pathol.</source><year>2021</year><volume>58</volume><fpage>809</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1177/0300985821999831</pub-id><pub-id pub-id-type="pmid">33769136</pub-id>
</element-citation></ref><ref id="B31-vetsci-12-00137"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hennequart</surname><given-names>M.</given-names></name>
<name><surname>Pilley</surname><given-names>S.E.</given-names></name>
<name><surname>Labuschagne</surname><given-names>C.F.</given-names></name>
<name><surname>Coomes</surname><given-names>J.</given-names></name>
<name><surname>Mervant</surname><given-names>L.</given-names></name>
<name><surname>Driscoll</surname><given-names>P.C.</given-names></name>
<name><surname>Legrave</surname><given-names>N.M.</given-names></name>
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Kreuzaler</surname><given-names>P.</given-names></name>
<name><surname>Macintyre</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>ALDH1L2 regulation of formate, formyl-methionine, and ROS controls cancer cell migration and metastasis</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112562</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112562</pub-id><pub-id pub-id-type="pmid">37245210</pub-id>
</element-citation></ref><ref id="B32-vetsci-12-00137"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moyer</surname><given-names>J.</given-names></name>
<name><surname>Lopez</surname><given-names>D.J.</given-names></name>
<name><surname>Balkman</surname><given-names>C.E.</given-names></name>
<name><surname>Sumner</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Factors associated with survival in dogs with a histopathological diagnosis of hepatocellular carcinoma: 94 cases (2007&#x02013;2018)</article-title><source>Open Vet. J.</source><year>2021</year><volume>11</volume><fpage>144</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.4314/ovj.v11i1.21</pub-id><pub-id pub-id-type="pmid">33898296</pub-id>
</element-citation></ref><ref id="B33-vetsci-12-00137"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bj&#x000f8;rn-Yoshimoto</surname><given-names>W.E.</given-names></name>
<name><surname>Underhill</surname><given-names>S.M.</given-names></name>
</person-group><article-title>The importance of the excitatory amino acid transporter 3 (EAAT3)</article-title><source>Neurochem. Int.</source><year>2016</year><volume>98</volume><fpage>4</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2016.05.007</pub-id><pub-id pub-id-type="pmid">27233497</pub-id>
</element-citation></ref><ref id="B34-vetsci-12-00137"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schmitt</surname><given-names>A.</given-names></name>
<name><surname>Zink</surname><given-names>M.</given-names></name>
<name><surname>Petroianu</surname><given-names>G.</given-names></name>
<name><surname>May</surname><given-names>B.</given-names></name>
<name><surname>Braus</surname><given-names>D.F.</given-names></name>
<name><surname>Henn</surname><given-names>F.A.</given-names></name>
</person-group><article-title>Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain</article-title><source>Neurosci. Lett.</source><year>2003</year><volume>347</volume><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/S0304-3940(03)00653-0</pub-id><pub-id pub-id-type="pmid">12873733</pub-id>
</element-citation></ref><ref id="B35-vetsci-12-00137"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schniepp</surname><given-names>R.</given-names></name>
<name><surname>Kohler</surname><given-names>K.</given-names></name>
<name><surname>Ladewig</surname><given-names>T.</given-names></name>
<name><surname>Guenther</surname><given-names>E.</given-names></name>
<name><surname>Henke</surname><given-names>G.</given-names></name>
<name><surname>Palmada</surname><given-names>M.</given-names></name>
<name><surname>Boehmer</surname><given-names>C.</given-names></name>
<name><surname>Rothstein</surname><given-names>J.D.</given-names></name>
<name><surname>Br&#x000f6;er</surname><given-names>S.</given-names></name>
<name><surname>Lang</surname><given-names>F.</given-names></name>
</person-group><article-title>Retinal colocalization and in vitro interaction of the glutamate transporter EAAT3 and the serum- and glucocorticoid-inducible kinase SGK1 [correction]</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2004</year><volume>45</volume><fpage>1442</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1167/iovs.03-0062</pub-id><pub-id pub-id-type="pmid">15111600</pub-id>
</element-citation></ref><ref id="B36-vetsci-12-00137"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maragakis</surname><given-names>N.J.</given-names></name>
<name><surname>Dietrich</surname><given-names>J.</given-names></name>
<name><surname>Wong</surname><given-names>V.</given-names></name>
<name><surname>Xue</surname><given-names>H.</given-names></name>
<name><surname>Mayer-Proschel</surname><given-names>M.</given-names></name>
<name><surname>Rao</surname><given-names>M.S.</given-names></name>
<name><surname>Rothstein</surname><given-names>J.D.</given-names></name>
</person-group><article-title>Glutamate transporter expression and function in human glial progenitors</article-title><source>Glia</source><year>2004</year><volume>45</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1002/glia.10310</pub-id><pub-id pub-id-type="pmid">14730707</pub-id>
</element-citation></ref><ref id="B37-vetsci-12-00137"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhong</surname><given-names>X.</given-names></name>
<name><surname>Yao</surname><given-names>L.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Ma</surname><given-names>Q.</given-names></name>
<name><surname>Huang</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Gao</surname><given-names>C.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Q.</given-names></name>
<etal/>
</person-group><article-title>Comprehensive analysis of potential correlation between solute Carrier 1A (SLC1A) family and lung adenocarcinoma</article-title><source>Int. J. Gen. Med.</source><year>2022</year><volume>15</volume><fpage>2101</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.2147/IJGM.S350986</pub-id><pub-id pub-id-type="pmid">35241927</pub-id>
</element-citation></ref><ref id="B38-vetsci-12-00137"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Landman</surname><given-names>B.A.</given-names></name>
<name><surname>Zhou</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Transforming medical imaging with Transformers? A comparative review of key properties, current progresses, and future perspectives</article-title><source>Med. Image Anal.</source><year>2023</year><volume>85</volume><fpage>102762</fpage><pub-id pub-id-type="doi">10.1016/j.media.2023.102762</pub-id><pub-id pub-id-type="pmid">36738650</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00137-f001"><label>Figure 1</label><caption><p>Representative axial phase computed tomography (CT) images of the enhancement hepatocellular carcinoma (HCC) (<bold>A</bold>&#x02013;<bold>D</bold>) and the mean HU of enhancement HCC and adjacent liver in arterial-phase images (<bold>E</bold>). Images depict pre-contrast (<bold>A</bold>), arterial (<bold>B</bold>), portal (<bold>C</bold>), and equilibrium (<bold>D</bold>) phases. Enhancement HCC was defined by the presence of discrete arteries within the tumor and a statistically higher enhancement in the arterial phase than in the adjacent liver ((<bold>E</bold>), <italic toggle="yes">p</italic> &#x0003c; 0.05). White circle: enhancement HCC; black arrows: necrotic and cystic areas in the HCC.</p></caption><graphic xlink:href="vetsci-12-00137-g001" position="float"/></fig><fig position="float" id="vetsci-12-00137-f002"><label>Figure 2</label><caption><p>Representative axial phase computed tomography (CT) images of the non-enhancement hepatocellular carcinoma (HCC) (<bold>A</bold>&#x02013;<bold>D</bold>) and the mean HU of the non-enhancement HCC and adjacent liver in arterial-phase images (<bold>E</bold>). Images depict pre-contrast (<bold>A</bold>), arterial (<bold>B</bold>), portal (<bold>C</bold>), and equilibrium (<bold>D</bold>) phases. Non-enhancement HCC was defined as a statistically lesser enhancement in the arterial phase than that in the adjacent liver ((<bold>E</bold>), <italic toggle="yes">p</italic> &#x0003c; 0.05). White circle: non-enhancement HCC; white arrow: adjacent liver.</p></caption><graphic xlink:href="vetsci-12-00137-g002" position="float"/></fig><table-wrap position="float" id="vetsci-12-00137-t001"><object-id pub-id-type="pii">vetsci-12-00137-t001_Table 1</object-id><label>Table 1</label><caption><p>The clinical findings in dogs with HCC and normal livers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CT Examination</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sex</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Bleed</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Recurrence</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Metastasis</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">G1</td><td align="center" valign="middle" rowspan="1" colspan="1">NL</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" rowspan="1" colspan="1">beagle</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G1</td><td align="center" valign="middle" rowspan="1" colspan="1">NL</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8</td><td align="center" valign="middle" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" rowspan="1" colspan="1">beagle</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G1</td><td align="center" valign="middle" rowspan="1" colspan="1">NL</td><td align="center" valign="middle" rowspan="1" colspan="1">1.4</td><td align="center" valign="middle" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" rowspan="1" colspan="1">beagle</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G1</td><td align="center" valign="middle" rowspan="1" colspan="1">NL</td><td align="center" valign="middle" rowspan="1" colspan="1">3.3</td><td align="center" valign="middle" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" rowspan="1" colspan="1">beagle</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" rowspan="1" colspan="1">N/A</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G2</td><td align="center" valign="middle" rowspan="1" colspan="1">enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" rowspan="1" colspan="1">Dachshund</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G2</td><td align="center" valign="middle" rowspan="1" colspan="1">enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" rowspan="1" colspan="1">West Highland White Terrier</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G2</td><td align="center" valign="middle" rowspan="1" colspan="1">enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">7.5</td><td align="center" valign="middle" rowspan="1" colspan="1">CM</td><td align="center" valign="middle" rowspan="1" colspan="1">Toy Poodle</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G3</td><td align="center" valign="middle" rowspan="1" colspan="1">non-enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">14.4</td><td align="center" valign="middle" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" rowspan="1" colspan="1">Shiba</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G3</td><td align="center" valign="middle" rowspan="1" colspan="1">non-enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" rowspan="1" colspan="1">Border Collies</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G3</td><td align="center" valign="middle" rowspan="1" colspan="1">non-enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">SF</td><td align="center" valign="middle" rowspan="1" colspan="1">Brussels griffon</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">G3</td><td align="center" valign="middle" rowspan="1" colspan="1">non-enhancement</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" rowspan="1" colspan="1">Shiba</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">non-enhancement</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shiba</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p>NL, Normal liver; CM, cast male; IM, intact male; SF, spayed female; IF, intact female.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-12-00137-t002"><object-id pub-id-type="pii">vetsci-12-00137-t002_Table 2</object-id><label>Table 2</label><caption><p>DEGs as q-value &#x0003c; 0.01 among enhancement HCC, non&#x02014;enhancement HCC, and normal liver.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ensembl Gene ID</th><th rowspan="3" colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin">Gene Symbol</th><th colspan="9" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Counts per Million Mapped Reads</th></tr><tr><th colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">G1</th><th colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">G2</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NL</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NL</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NL</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NL</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E-HCC</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">E-HCC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E-HCC</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENSCAFG00000019241</td><td colspan="2" align="left" valign="middle" rowspan="1">DUSP9</td><td align="right" valign="middle" rowspan="1" colspan="1">0</td><td align="right" valign="middle" rowspan="1" colspan="1">0</td><td colspan="2" align="right" valign="middle" rowspan="1">1</td><td align="right" valign="middle" rowspan="1" colspan="1">0</td><td align="right" valign="middle" rowspan="1" colspan="1">699</td><td colspan="2" align="right" valign="middle" rowspan="1">2</td><td align="right" valign="middle" rowspan="1" colspan="1">139</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENSCAFG00000028626</td><td colspan="2" align="left" valign="middle" rowspan="1">SLPI</td><td align="right" valign="middle" rowspan="1" colspan="1">18</td><td align="right" valign="middle" rowspan="1" colspan="1">2</td><td colspan="2" align="right" valign="middle" rowspan="1">3</td><td align="right" valign="middle" rowspan="1" colspan="1">2</td><td align="right" valign="middle" rowspan="1" colspan="1">269</td><td colspan="2" align="right" valign="middle" rowspan="1">3006</td><td align="right" valign="middle" rowspan="1" colspan="1">546</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENSCAFG00000001911</td><td colspan="2" align="left" valign="middle" rowspan="1">ALDH1L2</td><td align="right" valign="middle" rowspan="1" colspan="1">9</td><td align="right" valign="middle" rowspan="1" colspan="1">5</td><td colspan="2" align="right" valign="middle" rowspan="1">5</td><td align="right" valign="middle" rowspan="1" colspan="1">9</td><td align="right" valign="middle" rowspan="1" colspan="1">305</td><td colspan="2" align="right" valign="middle" rowspan="1">16</td><td align="right" valign="middle" rowspan="1" colspan="1">1775</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENSCAFG00000047783</td><td colspan="2" align="left" valign="middle" rowspan="1">N/A</td><td align="right" valign="middle" rowspan="1" colspan="1">43.7</td><td align="right" valign="middle" rowspan="1" colspan="1">123.42</td><td colspan="2" align="right" valign="middle" rowspan="1">60.84</td><td align="right" valign="middle" rowspan="1" colspan="1">70.61</td><td align="right" valign="middle" rowspan="1" colspan="1">1.4</td><td colspan="2" align="right" valign="middle" rowspan="1">0</td><td align="right" valign="middle" rowspan="1" colspan="1">4.94</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENSCAFG00000016090</td><td colspan="2" align="left" valign="middle" rowspan="1">TOP2A</td><td align="right" valign="middle" rowspan="1" colspan="1">16</td><td align="right" valign="middle" rowspan="1" colspan="1">11</td><td colspan="2" align="right" valign="middle" rowspan="1">6</td><td align="right" valign="middle" rowspan="1" colspan="1">18</td><td align="right" valign="middle" rowspan="1" colspan="1">116</td><td colspan="2" align="right" valign="middle" rowspan="1">175</td><td align="right" valign="middle" rowspan="1" colspan="1">620</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENSCAFG00000025465</td><td colspan="2" align="left" valign="middle" rowspan="1">TRPV6</td><td align="right" valign="middle" rowspan="1" colspan="1">317</td><td align="right" valign="middle" rowspan="1" colspan="1">123</td><td colspan="2" align="right" valign="middle" rowspan="1">191</td><td align="right" valign="middle" rowspan="1" colspan="1">153</td><td align="right" valign="middle" rowspan="1" colspan="1">55</td><td colspan="2" align="right" valign="middle" rowspan="1">1</td><td align="right" valign="middle" rowspan="1" colspan="1">56</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ENSCAFG00000012593</td><td colspan="2" align="left" valign="middle" rowspan="1">CENPF</td><td align="right" valign="middle" rowspan="1" colspan="1">4</td><td align="right" valign="middle" rowspan="1" colspan="1">4</td><td colspan="2" align="right" valign="middle" rowspan="1">4</td><td align="right" valign="middle" rowspan="1" colspan="1">4</td><td align="right" valign="middle" rowspan="1" colspan="1">24</td><td colspan="2" align="right" valign="middle" rowspan="1">90</td><td align="right" valign="middle" rowspan="1" colspan="1">280</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ENSCAFG00000002067</td><td colspan="2" align="left" valign="middle" style="border-bottom:solid thin" rowspan="1">SLC1A1</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1879</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1818</td><td colspan="2" align="right" valign="middle" style="border-bottom:solid thin" rowspan="1">1332</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2516</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">682</td><td colspan="2" align="right" valign="middle" style="border-bottom:solid thin" rowspan="1">815</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1204</td></tr><tr><td colspan="8" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">G3</td><td rowspan="2" colspan="2" align="center" valign="middle" style="border-bottom:solid thin"><italic toggle="yes">q</italic>-value</td><td rowspan="2" colspan="2" align="center" valign="middle" style="border-bottom:solid thin">DEG order</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE-HCC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NE-HCC</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NE-HCC</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NE-HCC</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">NE-HCC</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">0</td><td align="right" valign="middle" rowspan="1" colspan="1">0</td><td colspan="2" align="right" valign="middle" rowspan="1">1</td><td colspan="2" align="right" valign="middle" rowspan="1">0</td><td colspan="2" align="right" valign="middle" rowspan="1">0</td><td colspan="2" align="right" valign="middle" rowspan="1">0.004863</td><td colspan="2" align="right" valign="middle" rowspan="1">G2 &#x0003e; other</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">33</td><td align="right" valign="middle" rowspan="1" colspan="1">66</td><td colspan="2" align="right" valign="middle" rowspan="1">28</td><td colspan="2" align="right" valign="middle" rowspan="1">18</td><td colspan="2" align="right" valign="middle" rowspan="1">128</td><td colspan="2" align="right" valign="middle" rowspan="1">0.004863</td><td colspan="2" align="right" valign="middle" rowspan="1">G2 &#x0003e; other</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">22</td><td align="right" valign="middle" rowspan="1" colspan="1">14</td><td colspan="2" align="right" valign="middle" rowspan="1">33</td><td colspan="2" align="right" valign="middle" rowspan="1">18</td><td colspan="2" align="right" valign="middle" rowspan="1">14</td><td colspan="2" align="right" valign="middle" rowspan="1">0.005376</td><td colspan="2" align="right" valign="middle" rowspan="1">G2 &#x0003e; other</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">1.56</td><td align="right" valign="middle" rowspan="1" colspan="1">0</td><td colspan="2" align="right" valign="middle" rowspan="1">1.44</td><td colspan="2" align="right" valign="middle" rowspan="1">3.71</td><td colspan="2" align="right" valign="middle" rowspan="1">2.1</td><td colspan="2" align="right" valign="middle" rowspan="1">0.005387</td><td colspan="2" align="right" valign="middle" rowspan="1">0</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">254</td><td align="right" valign="middle" rowspan="1" colspan="1">176</td><td colspan="2" align="right" valign="middle" rowspan="1">673</td><td colspan="2" align="right" valign="middle" rowspan="1">398</td><td colspan="2" align="right" valign="middle" rowspan="1">166</td><td colspan="2" align="right" valign="middle" rowspan="1">0.008041</td><td colspan="2" align="right" valign="middle" rowspan="1">other &#x0003e; G1</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">0</td><td align="right" valign="middle" rowspan="1" colspan="1">3</td><td colspan="2" align="right" valign="middle" rowspan="1">1</td><td colspan="2" align="right" valign="middle" rowspan="1">0</td><td colspan="2" align="right" valign="middle" rowspan="1">0</td><td colspan="2" align="right" valign="middle" rowspan="1">0.009765</td><td colspan="2" align="right" valign="middle" rowspan="1">G1 &#x0003e; other</td></tr><tr><td align="right" valign="middle" rowspan="1" colspan="1">143</td><td align="right" valign="middle" rowspan="1" colspan="1">131</td><td colspan="2" align="right" valign="middle" rowspan="1">213</td><td colspan="2" align="right" valign="middle" rowspan="1">75</td><td colspan="2" align="right" valign="middle" rowspan="1">59</td><td colspan="2" align="right" valign="middle" rowspan="1">0.009765</td><td colspan="2" align="right" valign="middle" rowspan="1">other &#x0003e; G1</td></tr><tr><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="right" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td colspan="2" align="right" valign="middle" style="border-bottom:solid thin" rowspan="1">44</td><td colspan="2" align="right" valign="middle" style="border-bottom:solid thin" rowspan="1">0</td><td colspan="2" align="right" valign="middle" style="border-bottom:solid thin" rowspan="1">0</td><td colspan="2" align="right" valign="middle" style="border-bottom:solid thin" rowspan="1">0.009828</td><td colspan="2" align="right" valign="middle" style="border-bottom:solid thin" rowspan="1">other &#x0003e; G3</td></tr></tbody></table><table-wrap-foot><fn><p>Normal livers were grouped as G1, enhancement HCC as G2, and non-enhancement HCC as G3. NL, normal liver; E-HCC, enhancement HCC; NE-HCC, non-enhancement HCC.</p></fn></table-wrap-foot></table-wrap></floats-group></article>